Latest collaboration video

Watch the video on our collaboration with Guangzhou Medical University. We’re working together to advance the scientific understanding of Chronic Obstructive Pulmonary Disease in China.

Read more about this collaboration


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

banner_az_THM 29 September 2015

PI3K inhibition: the pathway to next-generation respiratory medicines?

CRISPR Conference

We are pleased to announce the inaugural Sanger Institute-AstraZeneca conference centred on the application of CRISPR technology to the understanding and treatment of human disease. Read More

CRISPR Conference

Latest press releases

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
30 September 2015
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)
24 September 2015
AstraZeneca to present data demonstrating diversity of its portfolio of innovative formulations and devices at the European Respiratory Society International Congress 2015
22 September 2015
AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes
17 September 2015
AstraZeneca announces new tolerability, long-term efficacy and real-world adherence data for exenatide once weekly in patients with type 2 diabetes
15 September 2015
AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015
11 September 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
11 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
8 September 2015
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015
4 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
3 September 2015
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
2 September 2015